Currently out of the existing stock ratings of Richard Law, 37 are a HOLD (50%), 33 are a BUY (44.59%), 4 are a SELL (5.41%).

Richard Law

Work Performance Price Targets & Ratings Chart

Analyst Richard Law, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 35.04% that have a potential upside of 42.16% achieved within 161 days. Previously, Richard Law worked at CREDIT SUISSE.

Richard Law’s has documented 149 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARVN, Arvinas at 14-Oct-2025.

Wall Street Analyst Richard Law

Analyst best performing recommendations are on FIXX (HOMOLOGY MEDICINES).
The best stock recommendation documented was for FIXX (HOMOLOGY MEDICINES) at 5/17/2022. The price target of $2.1 was fulfilled within 21 days with a profit of $0.59 (39.07%) receiving and performance score of 18.61.

Average potential price target upside

of $20.36 (144.62%) on MLYS (MINERALYS THERAPEUTICS, COMMON STOCK).
of $18.57 (35.38%) on CRSP (CRISPR THERAPEUTICS AG).
of $12.38 (42.66%) on KYMR (KYMERA THERAPEUTICS).

ARVN Arvinas BEAM Beam Therapeutics CRSP Crispr Therapeutics AG FIXX Homology Medicines KYMR Kymera Therapeutics NTLA Intellia Therapeutics EDIT Editas Medicine CCCC C4 Therapeutics GLUE Monte Rosa Therapeutics OLMA Olema Pharmaceuticals VERV Verve Therapeutics MLTX MoonLake Immunotherapeutics RCKT Rocket Pharmaceuticals VRDN Viridian Therapeutics MLYS Mineralys Therapeutics, Common Stock CLDX Celldex Therapeutics SLN Silence Therapeutics PLC

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Richard Law (GOLDMAN SACHS)